Abstract
Background: We performed a systematic review and meta-analysis of the risk of proteinuria associated with ramucirumab. Methods: Eligible studies included randomized phase II and III trials of patients with solid tumors on ramucirumab, describing events of all-grade and high-grade proteinuria. Results: Our search strategy yielded 170 potentially relevant citations from PubMed/Medline, CENTRAL Cochrane database, ASCO and ESMO meeting libraries. After exclusion of ineligible studies, a total of 11 clinical trials were considered eligible for the meta-analysis. The relative risk (RR) of all-grade proteinuria was 3.31 (95% CI 2.48-4.42; p < 0.00001). Moreover, the RR of high-grade proteinuria was 5.28 (95% CI 2.32-12.01; p < 0.0001). Conclusions: Our meta-analysis has demonstrated that ramucirumab use is associated with an increased risk of all-grade and high-grade proteinuria. Early detection strategies should be employed in those patients to prevent the progression to more sinister renal disease.
Journal Section:
Editor's choice
References
1.
Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z: Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002;97:393-399.
[PubMed]
2.
Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z: Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 2003;278:43496-43507.
[PubMed]
3.
Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G: Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014;2:123.
[PubMed]
4.
Wilke H, Muro K, Van Cutsem EV, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235.
[PubMed]
5.
Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39.
[PubMed]
6.
Abdel-Rahman, O: Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol 2015;93:18-27.
[PubMed]
7.
Bozza C, Fontanella C, Buoro V, Mansutti M, Aprile G: Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? Exp Rev Clin Pharmacol 2015;8:251-265.
[PubMed]
8.
Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F: Ramucirumab: preclinical research and clinical development. Onco Targets Ther 2014;7:1997.
[PubMed]
9.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-1012.
[PubMed]
10.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
[PubMed]
11.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
[PubMed]
12.
Yardley DA, Richards PD, Reeves JA, et al: Final results of a phase 2 study of ramucirumab (RAM) plus erbulin (E) versus E in advanced metastatic breast cancer (MBC). Abstract 1035. J Clin Oncol 2014;32(suppl):S5.
13.
Yoon HH, Bendell JC, Braiteh FS, et al: Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. Abstract 4004. J Clin Oncol 2014;32(suppl):S5.
14.
Doebele RC, Spigel D, Tehfe M, et al: Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 2015;121:883-892.
[PubMed]
15.
https://clinicaltrials.gov/ct2/show/results/NCT01160744?term=ramucirumab&rank= 38§=X01256#all (accessed March 31, 2015).
16.
Zhu AX, Ryoo BY, Yen CJ, et al: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: results from the randomized phase III REACH trial. Ann Oncol 2014;25(suppl 5):v1-v41.
17.
Garon EB, Ciuleanu TE, Arrieta O, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-673.
[PubMed]
18.
Hussain M, Rathkopf DE, Liu G, et al: A phase II randomized study of cixutumumab (IMC-A12:CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (patients) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy (abstract). J Clin Oncol 2012;30(suppl 5):97.
19.
Mackey JR, Ramos-Vazquez M, Lipatov O, et al: Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 2015;33:141- 148.
[PubMed]
20.
Tabernero J, Cohn AL, Obermannova R, et al: RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (patients) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 2015;16:499-508.
21.
Chung AS, Lee J, Ferrara N: Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-514.
[PubMed]
22.
Abdel-Rahman O: Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside. Crit Rev Oncol Hematol 2015;94:45-54.
[PubMed]
23.
Kerbel RS: Tumor angiogenesis. N Engl J Med 2008;358:2039-2049.
[PubMed]
24.
Abdel-Rahman O: Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumor Biol 2014;35:10615-10625.
[PubMed]
25.
http://emedicine.medscape.com/article/ 238158-overview (accessed April 24, 2015).
26.
Peng L, Zhao Q, Ye X, Zhou Y, Hu D, Zheng S: Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis. PLoS One 2014;9:e111839.
[PubMed]
27.
Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21:1381-1389.
[PubMed]
28.
Baek S, Kim H, Lee J, et al: Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 2014;29:40-48.
[PubMed]
29.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, et al: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-716.
[PubMed]
30.
Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, et al: VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46:439-448.
[PubMed]
31.
Larmour KE, Maxwell AP, Courtney AE: Improving early detection of chronic kidney disease. Practitioner 2015;259:19-23.
[PubMed]
32.
Lewis G, Maxwell AP: Timely diagnosis and treatment essential in glomerulonephritis. Practitioner 2015;259:13-17.
[PubMed]
33.
Warady BA, Abraham AG, Schwartz GJ, Wong CS, Muñoz A, Betoko A, Furth S: Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort. Am J Kidney Dis 2015;65:878-888.
[PubMed]
34.
Bakris GL: Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol 2008;3(suppl 1):S3-S10.
[PubMed]
35.
De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-2320.
[PubMed]
36.
Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA: Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007;7:2350-2360.
[PubMed]
37.
Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, et al: Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension 2014;64:1282-1289.
[PubMed]
38.
Kidney Disease Outcomes Quality Initiative: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(suppl 1):S1-290.
[PubMed]
39.
Dincer M, Altundag K: Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 2006;40:2278-2279.
[PubMed]
40.
Abdel-Rahman O, Alorabi M: Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. Expert Rev Anticancer Ther 2015;15:829-837.
[PubMed]
41.
http://pi.lilly.com/us/cyramza-pi.pdf (accessed April 1, 2015).
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
